First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
The AICVD tool can predict the risk of cardiovascular disease.
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
Subscribe To Our Newsletter & Stay Updated
